<html><head><meta content="text/html; charset=ISO-8859-1"http-equiv="Content-Type"><head><link rel="stylesheet" type="text/css" href="../malletgui.css" /><title>Doc150.html</title></head><table style=" text-align: left;" border="0" cellpadding="2" cellspacing="2"><tbody><body><h4><u>DOC</u> :150.txt</h4><br><textarea style="width: 50%; height: 150px;">Shares hit by MS drug suspension

Shares in Elan and Biogen Idec plunged on Monday as the firms suspended sales of new multiple sclerosis drug Tysabri after a patient's death in the US.

On the New York Stock Exchange, shares in Ireland-based Elan lost 70% while US partner Biogen Idec shed 43%. The firms took action after the death from a central nervous system disease and a suspected case of the condition. The cases cited involved the use of both Tysabri and Avonex, Biogen Idec's existing multiple sclerosis drug. The companies said they have no reports of the rare condition - progressive multifocal leukoencephalopathy (PML) - in patients taking either Tysabri or Avonex alon...</textarea><br><br>Top topics in this doc (% words in doc assigned to this topic) <br><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(31%)</td><td><a href=../Topics/Topic8.html>firms commission statement decision sec rules</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(17%)</td><td><a href=../Topics/Topic14.html>china bank market stock investors years</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(9%)</td><td><a href=../Topics/Topic5.html>bn shares deal offer bid firm</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(5%)</td><td><a href=../Topics/Topic19.html>growth dollar analysts fall japan demand</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(5%)</td><td><a href=../Topics/Topic15.html>year bn profits quarter expected profit</a> ...</td></tr></tbody></table><br><br><br><br><a href=../all_topics.html><b>[Index]</b></a></body></html>